Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutherland, Jessica E., Hettinger, Julia L., Chan, Amy, Gilbert, Jason, Warner, Garvin L., Davis, Wendell P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987735/
https://www.ncbi.nlm.nih.gov/pubmed/31821125
http://dx.doi.org/10.1089/nat.2019.0796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987735/
https://www.ncbi.nlm.nih.gov/pubmed/31821125
http://dx.doi.org/10.1089/nat.2019.0796

Ejemplares similares